Efforts focused on four areas: access and health equity, workforce and DE&I, community impact and the environment CAMBRIDGE, ...

Biogen is addressing profitability concerns and a lack of top-line growth. Read more to see an overview and analysis of BIIB ...

Biogen's Alzheimer therapy, Leqembi, is gaining traction with Q1'24 sales of $19m, nearly tripling Q4 revenues. Read my ...

Viehbacher's pay that year was exceeded only by Jason Robins, the CEO of DraftKings, and Douglas Ingram, president and chief ...

In the preceding three months, 27 analysts have released ratings for Biogen (NASDAQ:BIIB), presenting a wide array of ...

Investors and analysts are so used to bad news from Biogen (BIIB) that they seemingly didn’t know how to react when the ...

Biogen and Eisai are ready to ramp up their Leqembi sales and marketing push. After a slow start, Biogen is now planning to ...

While Biogen’s Chris Viehbacher figures the company is “turning the corner” after several recent setbacks—thanks in large ...

Biogen beat Wall Street estimates for first-quarter profit on Wednesday, helped by a series of cost-cutting measures as older ...

Biogen shares gained ground before market open Wednesday, after the company reported first-quarter profit that beat analysts’ ...

Biogen beat market estimates for first-quarter profit on Wednesday as a series of cost-cutting measures helped offset the ...

Revenue missed analyst estimates by 1.1%. Earnings per share (EPS) exceeded analyst estimates by 2.3%. Looking ahead, revenue ...